VanEck Associates’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.71M | Sell |
40,254
-556,476
| -93% | -$134M | 0.01% | 494 |
|
|
2025
Q1 | $145M | Sell |
596,730
-126,741
| -18% | -$30.9M | 0.19% | 117 |
|
|
2024
Q4 | $238M | Sell |
723,471
-580,281
| -45% | -$191M | 0.3% | 82 |
|
|
2024
Q3 | $437M | Buy |
1,303,752
+644,530
| +98% | +$216M | 0.55% | 44 |
|
|
2024
Q2 | $180M | Buy |
+659,222
| New | +$180M | 0.26% | 102 |
|
|
2022
Q3 | – | Sell |
-1,813
| Closed | -$897K | – | 1388 |
|
|
2022
Q2 | $897K | Sell |
1,813
-201
| -10% | -$99.4K | ﹤0.01% | 813 |
|
|
2022
Q1 | $1.13M | Buy |
2,014
+525
| +35% | +$296K | ﹤0.01% | 811 |
|
|
2021
Q4 | $1.13M | Buy |
1,489
+232
| +18% | +$175K | ﹤0.01% | 825 |
|
|
2021
Q3 | $938K | Buy |
1,257
+88
| +8% | +$65.7K | ﹤0.01% | 821 |
|
|
2021
Q2 | $753K | Buy |
1,169
+47
| +4% | +$30.3K | ﹤0.01% | 848 |
|
|
2021
Q1 | $641K | Buy |
1,122
+48
| +4% | +$27.4K | ﹤0.01% | 817 |
|
|
2020
Q4 | $626K | Buy |
1,074
+716
| +200% | +$417K | ﹤0.01% | 750 |
|
|
2020
Q3 | $185K | Buy |
+358
| New | +$185K | ﹤0.01% | 828 |
|